A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2016
At a glance
- Drugs Axitinib (Primary) ; Selenomethionine
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 07 Nov 2016 Status changed from suspended to recruiting.
- 24 Oct 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 24 Oct 2016 Status changed from recruiting to suspended.